When combined with increased physical activity and a low-calorie diet, semaglutide (Wegovy) is indicated for weight management in patients with: Obesity (BMI of 30 kg/m or higher) Overweight (BMI of 27 kg/m or higher) with at least one weight-related health condition such as high cholesterol levels, hypertension (high blood pressure), heart disease, and type 2 diabetes Mechanism of action Semaglutide is a GLP-1 agonist that slows digestion, reduces appetite, and stabilizes blood sugar by working in the following ways: It mimics the action of glucagon-like peptide-1 in the lateral hypothalamus (hunger control centre), which suppresses appetite and gives you a feeling of satiety
For patients with obesity-related comorbidities such as hypertension, dyslipidaemia, or fatty liver disease these combined effects could represent a clinically meaningful advance if confirmed in Phase 3 data
Managing Side Effects During Dose Increases Mild nausea, reduced appetite for favorite foods, and slight stomach discomfort are common during the first two weeks at each new dose level and typically fade as your body adjusts
It reflects the pharmacokinetic reality of clearing one medication while building another to steady state
Always dispose of used syringes in a puncture-resistant sharps container